KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Goodwill & Intangibles: 2018-2024

Historic Goodwill & Intangibles for Castle Biosciences (CSTL) over the last 5 years, with Dec 2024 value amounting to $106.2 million.

  • Castle Biosciences' Goodwill & Intangibles fell 7.89% to $101.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $101.8 million, marking a year-over-year decrease of 7.89%. This contributed to the annual value of $106.2 million for FY2024, which is 9.47% down from last year.
  • According to the latest figures from FY2024, Castle Biosciences' Goodwill & Intangibles is $106.2 million, which was down 9.47% from $117.3 million recorded in FY2023.
  • In the past 5 years, Castle Biosciences' Goodwill & Intangibles registered a high of $126.3 million during FY2022, and its lowest value of $88.9 million during FY2021.
  • Its 3-year average for Goodwill & Intangibles is $116.6 million, with a median of $117.3 million in 2023.
  • Its Goodwill & Intangibles has fluctuated over the past 5 years, first spiked by 42.09% in 2022, then declined by 9.47% in 2024.
  • Castle Biosciences' Goodwill & Intangibles (Yearly) stood at $88.9 million in 2021, then surged by 42.09% to $126.3 million in 2022, then dropped by 7.13% to $117.3 million in 2023, then dropped by 9.47% to $106.2 million in 2024.